STOCK TITAN

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
INOVIO's CEO, Dr. Jacqueline Shea, will participate in The Novel Therapeutics Forum hosted by Citizens JMP to discuss innovative technologies for treating and preventing diseases.
Positive
  • None.
Negative
  • None.

PLYMOUTH MEETING, Pa., March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.

Dr. Shea will provide a brief overview of INOVIO and then participate in a panel discussion entitled "Innovative Technologies for Treating and Preventing Disease," which will be moderated by Roy Buchanan, biotechnology analyst at Citizens JMP.

The Citizens JMP Novel Therapeutics Forum will take place at the Jordan Medical Education Center at the Perelman Center for Advanced Medicine but will not be webcast.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

Cision View original content:https://www.prnewswire.com/news-releases/inovio-to-participate-in-the-citizens-jmp-novel-therapeutics-forum-at-penn-medicine-302100288.html

SOURCE INOVIO Pharmaceuticals, Inc.

Dr. Jacqueline Shea will participate in The Novel Therapeutics Forum on April 2, 2024, at 10:00 am ET.

INOVIO is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases.

The panel discussion at The Novel Therapeutics Forum will be moderated by Roy Buchanan, a biotechnology analyst at Citizens JMP.

The Citizens JMP Novel Therapeutics Forum will take place at the Jordan Medical Education Center at the Perelman Center for Advanced Medicine.

No, the forum will not be webcasted.
Inovio Pharmaceuticals Inc

NASDAQ:INO

INO Rankings

INO Latest News

INO Stock Data

Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Small Arms, Ordnance, and Ordnance Accessories Manufacturing
US
San Diego

About INO

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.